Click here - to use the wp menu builder

BryoLogyx Names Omar Duramad, Ph.D., as Chief Scientific Officer

July 30, 2019

DANVILLE, Calif.–(BUSINESS WIRE)–BryoLogyx appoints Omar Duramad, Ph.D. as Chief Scientific Officer to lead preclinical development of bryostatin and analogues…

http://www.businesswire.com/news/home/20190730005289/en/BryoLogyx-Names-Omar-Duramad-Ph.D.-Chief-Scientific

BryoLogyx Names Omar Duramad, Ph.D., as Chief Scientific Officer

Recent Articles

Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod

AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer

Xentria Announces Submission of an Investigational New Drug (IND) Application for XTMAB-16 in the Treatment of Sarcoidosis

Quantum Materials Corp Expands Executive Leadership Team To Execute Growth Strategy

Repertoire Immune Medicines Pre-publishes New Research Identifying Potential Mechanisms for Immune Escape of SARS-CoV-2 Variants to Support Novel Approaches for T Cell Based Therapeutic...